- In January 2024, OncoRay launched the world’s first research prototype for complete body MRI-guided proton therapy. This innovative system integrates real-time MRI tracking with proton therapy, enabling accurate targeting of tumors, even those that move. The technology is expected to improve treatment precision, minimizing radiation exposure to healthy tissues and enhancing the overall effectiveness of cancer treatment by adapting to tumor movement during therapy sessions
- In October 2023, Hitachi, Ltd. delivered a state-of-the-art proton therapy system to the National Cancer Centre Singapore (NCCS), marking a significant milestone in the company's expansion into Southeast Asia. This installation strengthens Hitachi's position in the region’s healthcare sector and enhances access to cutting-edge proton therapy treatments, which are known for their precision and ability to target tumors while sparing surrounding healthy tissue
- In September 2023, At the American Society for Radiation Oncology (ASTRO) 2023 annual meeting in California, Siemens Healthineers AG, through its Varian Medical Systems subsidiary, showcased its advanced proton therapy technologies. This event highlighted Siemens' ongoing commitment to innovation in cancer treatment. By presenting the latest in proton therapy advancements, Siemens aims to improve clinical outcomes and patient care in radiation oncology
- In July 2023, Hitachi, Ltd. successfully delivered a proton therapy system to the HKSH Medical Group, which includes the Hong Kong Sanatorium and Hospital (HKSH). This installation marks the introduction of proton therapy in Hong Kong, providing advanced cancer treatment capabilities. The system, now in operation, offers precise tumor targeting with minimal damage to surrounding healthy tissue, enhancing the treatment options available for patients in the region
- In May 2022, Mevion Medical Systems was selected to install its MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS) at a comprehensive hospital in Southern China. This advanced system is designed to deliver highly targeted radiation therapy, improving treatment precision. The installation is a significant step in expanding access to proton therapy in China, offering patients a cutting-edge treatment option for various cancers
- In April 2022, The Connecticut Office of Health Strategy (OHS) approved the certificate of need application for Hartford HealthCare Corporation and Yale New Haven Health Services Corporation to establish proton therapy services. This approval allows the creation of the Connecticut Proton Therapy Center, a collaborative effort aimed at providing advanced proton therapy treatment to patients, ensuring more precise cancer treatment while minimizing the impact on surrounding healthy tissues
- In December 2021, Moffitt Cancer Center announced the construction of a new proton therapy treatment facility as part of its ongoing expansion. The facility will enable radiation oncologists to provide highly precise, targeted proton therapy. This technology allows for delivering radiation doses that effectively treat cancer cells while protecting surrounding healthy tissue, offering a safer and more efficient treatment option for cancer patients
- In September 2021, ProTom International entered into an agreement with the Behnke Group to expand its presence in the United States market. This strategic partnership will leverage the Behnke Group's industry connections to increase access to ProTom's advanced proton therapy treatments. The collaboration aims to help more cancer patients benefit from proton therapy, a highly precise form of radiation therapy that targets tumors while sparing healthy tissue
- In April 2020, Mevion Medical Systems received a medical device license from Health Canada for its MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS). This regulatory approval allows the system to be used in Canadian healthcare facilities. The system’s advanced capabilities in delivering precise, targeted radiation therapy offer an innovative approach to cancer treatment, minimizing damage to healthy tissue and improving patient outcomes
Frequently Asked Questions
The market is segmented based on Segmentation, By Therapy Type (Proton Therapy, Heavy Ion Therapy, and Fast-Neutron Therapy), Component Type (Products and Services), System (Multi-Room Systems and Single-Room Systems), Cancer Type (Paediatric Cancer, Prostate Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancer, and Other Cancers), Application (Treatment Application and Research Application) – Industry Trends and Forecast to 2032
.
The Global Particle Therapy Market size was valued at USD 1.69 USD Billion in 2024.
The Global Particle Therapy Market is projected to grow at a CAGR of 9.45% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
